Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood loss monitor could make surgery safer

NCT ID NCT07617428

Knowledge-focused Sponsor: Lanzhou University Second Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new device that automatically measures how much blood a patient loses during surgery. Current methods like visual estimation can be inaccurate. The device will be compared to several standard methods in 120 adults undergoing urological or general surgery. The goal is to see if it gives more precise readings without interfering with the operation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Novel multifunctional intraoperative blood loss monitoring system (device)
What this could lead to
If successful, this device could provide surgeons with more accurate, real-time blood loss measurements during surgery, potentially improving patient safety and reducing complications.
What could go wrong
This is an early observational study, not a treatment trial. The device may not prove more accurate than existing methods, and results may not apply to all surgery types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will be recruited from adult patients undergoing elective urological and general surgical procedures at two tertiary hospitals in China, including Lanzhou University Second Hospital and Lanzhou University First Hospital. Participants will be selected from routine clinical practice settings where intraoperative blood loss monitoring is required. This population represents adult surgical patients managed under standard perioperative care, providing a real-world clinical context for evaluating intraoperative blood loss measurement methods.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing elective urological or general surgical procedures * Age 18 years or older * Preoperative hemoglobin concentration available * Intraoperative blood loss assessment required during surgery Exclusion Criteria: * Patients with incomplete intraoperative blood loss measurement data, * Severe hemolysis or other conditions that may affect hemoglobin measurement * Emergency surgery * Intraoperative blood loss assessment required during surgery 24 hours after surgery * Refusal to participate, when applicable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intraoperative blood loss are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intraoperative blood loss

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gansu Provincial People's Hospital

    Lanzhou, Gansu, 730030, China

  • Lanzhou University Frist Hospital

    Lanzhou, Gansu, 730030, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, 730030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.